Sign Up
OverviewAPI
Addex Therapeutics enters into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC for potential sales of ADSs up to $2.1 million. ADX71149, their lead drug candidate, is in a Phase 2 clinical trial for epilepsy treatment. Indivior PLC has licensed Addex's GABAB PAM program for substance use disorder drug candidates.

Ask a question